Pfizer Inc. (NYSE:PFE) Stock Holdings Decreased by Savant Capital LLC

Savant Capital LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 7.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 234,529 shares of the biopharmaceutical company’s stock after selling 17,961 shares during the period. Savant Capital LLC’s holdings in Pfizer were worth $6,222,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Ritholtz Wealth Management boosted its holdings in shares of Pfizer by 26.3% in the 3rd quarter. Ritholtz Wealth Management now owns 55,267 shares of the biopharmaceutical company’s stock valued at $1,599,000 after buying an additional 11,519 shares during the period. Retirement Planning Group LLC acquired a new position in shares of Pfizer in the 3rd quarter valued at about $354,000. Exchange Traded Concepts LLC boosted its holdings in shares of Pfizer by 117.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 69,178 shares of the biopharmaceutical company’s stock valued at $2,002,000 after buying an additional 37,293 shares during the period. Willis Investment Counsel boosted its holdings in shares of Pfizer by 0.5% in the 3rd quarter. Willis Investment Counsel now owns 1,297,206 shares of the biopharmaceutical company’s stock valued at $37,541,000 after buying an additional 6,966 shares during the period. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its stake in Pfizer by 11.4% during the 3rd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 2,286,226 shares of the biopharmaceutical company’s stock valued at $66,163,000 after purchasing an additional 233,900 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.5 %

NYSE PFE opened at $25.87 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s 50 day simple moving average is $26.28 and its 200 day simple moving average is $27.72. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a market capitalization of $146.58 billion, a P/E ratio of 18.34, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the firm earned $0.10 EPS. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.65%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s payout ratio is presently 121.99%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PFE. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. Finally, Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.